Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

imara inc. - ELVN

ELVN

Close Chg Chg %
20.03 -0.14 -0.70%

Closed Market

19.89

-0.14 (0.70%)

Volume: 400.37K

Last Updated:

May 14, 2025, 4:00 PM EDT

Trade Now

Company Overview: imara inc. - ELVN

ELVN Key Data

Open

$19.98

 Day Range

19.53 - 20.96

52 Week Range

13.30 - 30.01

 Market Cap

$982.79M

Shares Outstanding

49.07M

 Public Float

31.84M

Beta

1.06

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.90

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

298.71K

  

ELVN Performance

1 Week
 
 7.98%
 
1 Month
 
 20.33%
 
3 Months
 
 -8.26%
 
1 Year
 
 -13.67%
 
5 Years
 
 N/A
 

ELVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About imara inc. - ELVN

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

ELVN At a Glance

Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
Phone 1-720-647-8519 Revenue 0.00
Industry Biotechnology Net Income -89,024,000.00
Sector Health Technology Employees 62
Fiscal Year-end 12 / 2025
View SEC Filings

ELVN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.554
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -7.153
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

ELVN Efficiency

Revenue/Employee N/A
Income Per Employee -1,435,870.968
Receivables Turnover N/A
Total Asset Turnover N/A

ELVN Liquidity

Current Ratio 19.989
Quick Ratio 19.989
Cash Ratio 19.698

ELVN Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -29.792
Return on Equity -32.037
Return on Total Capital -28.732
Return on Invested Capital -32.037

ELVN Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Imara Inc. - ELVN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
99.00K 622.00K 297.00K 317.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
99.00K 622.00K 297.00K 317.00K
Depreciation
99.00K 622.00K 297.00K 317.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+2.06% +528.28% -52.25% +6.73%
Gross Income
(99.00K) (622.00K) (297.00K) (317.00K)
Gross Income Growth
-2.06% -528.28% +52.25% -6.73%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
51.34M 33.65M 83.23M 104.24M
Research & Development
38.44M 18.94M 64.28M 80.46M
Other SG&A
12.90M 14.71M 18.95M 23.78M
SGA Growth
+23.42% -34.46% +147.36% +25.24%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (873.00K)
-
EBIT after Unusual Expense
(51.44M) (34.27M) (83.53M) (103.68M)
Non Operating Income/Expense
58.00K 35.85M 11.95M 14.89M
Non-Operating Interest Income
233.00K 943.00K 11.97M 14.89M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(51.38M) 1.58M (71.58M) (88.79M)
Pretax Income Growth
-24.24% +103.07% -4,642.13% -24.04%
Pretax Margin
- - - -
-
Income Tax
- - 88.00K 232.00K
-
Income Tax - Current - Domestic
- - - 232.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(51.38M) 1.49M (71.58M) (89.02M)
Minority Interest Expense
- - - -
-
Net Income
(51.38M) 1.49M (71.58M) (89.02M)
Net Income Growth
-24.24% +102.90% -4,910.75% -24.36%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(51.38M) 1.49M (71.58M) (89.02M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(51.38M) 1.49M (71.58M) (89.02M)
EPS (Basic)
-9.4886 0.2264 -2.0138 -1.8912
EPS (Basic) Growth
+32.89% +102.39% -989.49% +6.09%
Basic Shares Outstanding
5.42M 6.57M 35.55M 47.07M
EPS (Diluted)
-9.4886 0.2264 -2.0138 -1.8912
EPS (Diluted) Growth
+32.89% +102.39% -989.49% +6.09%
Diluted Shares Outstanding
5.42M 6.57M 35.55M 47.07M
EBITDA
(51.34M) (33.65M) (83.23M) (104.24M)
EBITDA Growth
-23.42% +34.46% -147.36% -25.24%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 37.875
Number of Ratings 9 Current Quarters Estimate -0.537
FY Report Date 06 / 2025 Current Year's Estimate -2.232
Last Quarter’s Earnings -0.57 Median PE on CY Estimate N/A
Year Ago Earnings -1.89 Next Fiscal Year Estimate -2.621
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 10 8
Mean Estimate -0.54 -0.57 -2.23 -2.62
High Estimates -0.48 -0.49 -1.89 -1.77
Low Estimate -0.61 -0.67 -2.59 -3.77
Coefficient of Variance -7.29 -10.99 -10.13 -24.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Imara Inc. - ELVN

Date Name Shares Transaction Value
Mar 24, 2025 Joseph P. Lyssikatos CHIEF SCIENTIFIC OFFICER 1,002,688 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.61 per share 20,665,399.68
Mar 21, 2025 Samuel S. Kintz PRESIDENT AND CEO; Director 990,392 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.83 per share 20,629,865.36
Mar 12, 2025 Anish Patel CHIEF OPERATING OFFICER 323,310 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.44 per share 6,931,766.40
Mar 7, 2025 Benjamin Hohl CHIEF FINANCIAL OFFICER 132,806 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Benjamin Hohl CHIEF FINANCIAL OFFICER 23,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.48 per share 57,040.00
Oct 4, 2024 Richard A. Heyman Director 128,585 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.54 per share 3,541,230.90
Oct 4, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER 192,358 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Richard A. Heyman Director 130,373 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.7 per share 3,089,840.10
Jul 17, 2024 Anish Patel CHIEF OPERATING OFFICER 345,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.05 per share 8,656,628.70
Jul 17, 2024 Anish Patel CHIEF OPERATING OFFICER 344,027 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.01 per share 8,604,115.27
Jun 28, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 1,075,525 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.3 per share 23,984,207.50
Jun 11, 2024 Anish Patel CHIEF OPERATING OFFICER 53,342 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 188,841 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.34 per share 0.00
May 31, 2024 Samuel S. Kintz PRESIDENT AND CEO; Director 100 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.57 per share 2,357.00
May 31, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.34 per share 0.00
May 31, 2024 Benjamin Hohl CHIEF FINANCIAL OFFICER 216,870 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2024 OrbiMed Advisors Private Equity Director 7,663,349 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.14 per share 169,666,546.86
May 21, 2024 OrbiMed Advisors Private Equity Director 254,814 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.14 per share 5,641,581.96

Imara Inc. in the News